MedPath

Meloxicam

Generic Name
Meloxicam
Brand Names
Anjeso, Mobic, Qmiiz, Vivlodex
Drug Type
Small Molecule
Chemical Formula
C14H13N3O4S2
CAS Number
71125-38-7
Unique Ingredient Identifier
VG2QF83CGL

Overview

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.

Indication

Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain. Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Associated Conditions

  • Dental Pain
  • Neuropathic Pain
  • Osteoarthritis (OA)
  • Pain, Inflammatory
  • Pauciarticular juvenile rheumatoid arthritis
  • Polyarticular juvenile rheumatoid arthritis, chronic or unspecified
  • Postoperative pain
  • Rheumatoid Arthritis

Clinical Trials

View More Clinical Trials

Sign in to access the complete clinical trial database with detailed study information.

Title
Posted
Study ID
Phase
Status
Sponsor
2021/10/28
Not Applicable
Completed
Alfarabi Colleges
2021/02/25
N/A
Completed
2021/02/23
Phase 4
Terminated
2021/01/26
Phase 3
UNKNOWN
2020/07/29
Phase 1
UNKNOWN
Daewoong Pharmaceutical Co. LTD.
2020/07/21
Phase 2
UNKNOWN
Shanghai University of Traditional Chinese Medicine
2020/03/26
Phase 1
UNKNOWN
Beijing Tongren Hospital
2019/10/03
Phase 2
Terminated
2019/07/01
Not Applicable
Completed
2019/03/29
Phase 3
Completed

FDA Drug Approvals

View More FDA Approvals

Sign in to access additional FDA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
Strides Pharma Science Limited
64380-716
ORAL
15 mg in 1 1
5/28/2021
Denton Pharma, Inc. DBA Northwind Pharmaceuticals
70934-010
ORAL
7.5 mg in 1 1
2/1/2023
Denton Pharma, Inc. DBA Northwind Pharmaceuticals
70934-011
ORAL
15 mg in 1 1
1/10/2023
Zydus Lifesciences Limited
65841-050
ORAL
7.5 mg in 1 1
10/18/2022
RedPharm Drug, Inc.
67296-0823
ORAL
15 mg in 1 1
2/15/2023
STAT Rx USA LLC
42549-604
ORAL
7.5 mg in 1 1
2/23/2012
Boehringer Ingelheim Animal Health USA Inc.
0010-6014
ORAL
0.05 g in 100 mL
5/2/2025
Aphena Pharma Solutions - Tennessee, LLC
71610-583
ORAL
7.5 mg in 1 1
3/3/2022
Bryant Ranch Prepack
71335-1956
ORAL
15 mg in 1 1
8/16/2021
Zydus Lifesciences Limited
65841-051
ORAL
15 mg in 1 1
10/18/2022

EMA Drug Approvals

View More EMA Approvals

Sign in to access additional EMA-approved drug information with detailed regulatory data.

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

View More HSA Approvals

Sign in to access additional HSA-approved drug information with detailed regulatory data.

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

View More NMPA Approvals

Sign in to access additional NMPA-approved drug information with detailed regulatory data.

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

View More PPB Approvals

Sign in to access additional PPB-approved drug information with detailed regulatory data.

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

Health Canada Drug Approvals

View More Health Canada Approvals

Sign in to access additional Health Canada approved drug information with detailed regulatory data.

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
MELOXICAM
Cobalt Pharmaceuticals Company
02343428
Tablet - Oral
15 MG
N/A
MELOXICAM
PRO DOC LIMITEE
02324326
Tablet - Oral
7.5 MG
6/10/2009
PMS-MELOXICAM
02248267
Tablet - Oral
7.5 MG
11/7/2003
DOM-MELOXICAM
dominion pharmacal
02248605
Tablet - Oral
7.5 MG
2/6/2004
PMS-MELOXICAM
02248268
Tablet - Oral
15 MG
11/7/2003
APO-MELOXICAM
02248973
Tablet - Oral
7.5 MG
2/13/2004
ACT MELOXICAM
teva canada limited
02250020
Tablet - Oral
15 MG
8/12/2004
MELOXICAM
sanis health inc
02353148
Tablet - Oral
7.5 MG
7/26/2010
AVA-MELOXICAM
avanstra inc
02365553
Tablet - Oral
15.0 MG
8/11/2011
AURO-MELOXICAM
auro pharma inc
02390892
Tablet - Oral
15 MG
10/18/2012

CIMA AEMPS Drug Approvals

View More CIMA AEMPS Approvals

Sign in to access additional CIMA AEMPS approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
MELOXICAM STADA 15 mg COMPRIMIDOS EFG
Laboratorio Stada S.L.
66400
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Commercialized
MELOXICAM KERN PHARMA 15 mg COMPRIMIDOS EFG
66524
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Not Commercialized
MOVALIS 15 mg COMPRIMIDOS
61076
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Commercialized
MELOXICAM SANDOZ 7,5 mg COMPRIMIDOS EFG
Sandoz Farmaceutica S.A.
66362
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Not Commercialized
MELOXICAM SANDOZ 15 mg COMPRIMIDOS EFG
Sandoz Farmaceutica S.A.
66361
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Not Commercialized
MELOXICAM PENSA 15 mg COMPRIMIDOS EFG
Towa Pharmaceutical S.A.
68844
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Commercialized
MELOXICAM SUMOL 15 mg COMPRIMIDOS EFG
Sumol Pharma S.A.
66832
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Not Commercialized
MELOXICAM SUMOL 7,5 mg COMPRIMIDOS EFG
Sumol Pharma S.A.
66831
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Not Commercialized
MELOXICAM MYLAN 7.5 mg COMPRIMIDOS EFG
Mylan Pharmaceuticals S.L.
66411
COMPRIMIDO
Medicamento Sujeto A Prescripción Médica
Not Commercialized

Philippines FDA Drug Approvals

View More Philippines FDA Approvals

Sign in to access additional Philippines FDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

View More Saudi SFDA Approvals

Sign in to access additional Saudi SFDA approved drug information with detailed regulatory data.

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

View More Malaysia NPRA Approvals

Sign in to access additional Malaysia NPRA approved drug information with detailed regulatory data.

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

View More UK EMC Drug Information

Sign in to access additional UK EMC drug information with detailed pharmaceutical data.

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.